Pay in 4 interest-free payments of $7.39 Learn more
Ships within 48 hours · Estimated delivery Aug 17 - Aug 22
Ozempic is paving the way for other GLP-1 drugs to treat conditions beyond kidney disease The FLOW trial results, along with the recent announcement that Wegovy is approved to reduce cardiovascular risk in people with obesity, are the latest indications that these drugs have benefits for conditions beyond their original intended treatment of type 2 diabetes
Carroll, J
The genetics of obesity: from discovery to biology
Does oral GLP-1 work for weight loss
US$ 24.70
US$ 29.55
US$ 26.62
US$ 21.49
US$ 23.70
US$ 22.64
US$ 20.34
US$ 27.49
US$ 22.23
US$ 26.79
US$ 24.21
